Each vial contains 50 ml human normal immunoglobulin BP containing ≥ 2500 mg of human immunoglobulin-G (IgG)
Normoglobin is a ready to use, sterile, clear or slightly opalescent and colorless to pale yellow, liquid preparation of purified immunoglobulin-G (IgG) obtained from human plasma pools. The purification processes include thawing, cold ethanol fractionation, chromatography, virus inactivation with S/D fractionation and nano-filtration and dia-filtration. The final bulk is manufactured by adding maltose (as stabilizer) to bulk product and passing through sterile filter, after this the final bulk is filled into vials.
• For combined therapy with antibioticsin severe bacterial or viral infections
• Idiopathic Thrombocytopenic Purpura
• Guillain-Barre Syndrome
• Kawasaki Syndrome
• Primary immunodeficiency
Dosage and Administration:
For combined therapy with antibiotics in severe bacterial or viral infections and
The usual dosage for adults and children is 2500-5000 mg and 50-150 mg/kg respectively (as a single dose) by intravenous drip infusion or direct intravenous infusion. In case of intravenous injection, it should be injected very slowly.
For Idiopathic Thrombocytopenic Purpura:
The usual dose is 200-400 mg/kg daily given for 5 consecutive days. The additional doses are discontinued if an adequate response does not occur.
For Guillain-Barre Syndrome:
The usual dosage is 400 mg/kg daily given for 5 consecutive days.
For Kawasaki Syndrome:
The usual dosage is 400 mg/kg daily given for 5 consecutive days (approximately) or 2000 mg daily by intravenous drip infusion. It is recommended that the administration start within 7 days from the onset of Kawasaki Syndrome.
For Primary immunodeficiency:
Human normal immunoglobulin is indicated in adults and pediatric patients of 2 years of age and older for the treatment of primary immunodeficiency (PI). The usual dose is 300-600 mg/kg body weight in every 3-4 weeks.
Method of administration
The human normal immunoglobulin is for intravenous use only. For intravenous injection, it should be injected very slowly. The product should be warmed to room or body temperature before use. The human normal immunoglobulin should be infused intravenously at the following rates:
0.01~0.02ml/kg/min for first 30 minutes and then infusion rate can be gradually increased maximum 0.06ml/kg/min, if no abnormal sign appears from patients. This can be recalculated by hourly basis; it is 0.6~1.2ml/kg/hr and 3.6ml/kg/hr (maximum).
• Symptoms of shock may occur. If dyspnea, wheeze, chest pain, hypotension or weak pulse are watched, administration should be discontinued and 0.1-0.5 ml epinephrine (1:1000) or the administration of cortisone should be considered.
• Rapid administration can cause hypotension.
• Liver function disorders or jaundice accompanying and increase in ALT or AST may occur. Caution should be taken and proper treatment should be followed if needed.
• Renal failure may occur with the use of human normal immunoglobulin. If dehydration, hypouresis, increase of creatinine or increase of BUN etc is observed, administration should be discontinued and proper treatment should be taken.
• Aseptic meningitis from a large volume of human normal immunoglobulin administration (Nuchalrigidity, fever, headache, nausea, vomiting, mental fog, etc.) may occur. In these cases, administration should be discontinued and proper treatment taken.
• Decrease in platelets may occur.Caution should be taken. If this symptom occurs, proper treatment should be taken.
• Other possible undesirable effects include drowsiness, chill, chest pain, abdominal pain, gluteal pain and anxiety etc.
• Severe hypersensitivity reactions and anaphylactic reactions with a fall in blood pressure may occur. Patients with antibodies to IgA have a greater risk of developing potentially severe hypersensitivity and anaphylactic reactions.
• Patients with renal disorder (Renal function may deteriorate), acute renal dysfunction/failure, acute tubular necrosis, proximal tubular nephropathy, osmotic nephrosis and death have been reported in patients receiving IVIG. It should be ensured that patients are not volume-depleted before administration of the IVIG. For patients judged to be at risk for developing renal dysfunction, including patients with any degree of pre-existing renal insufficiency, diabetes mellitus, age greater than 65, volume depletion, sepsis, paraproteinemia, or patients receiving known nephrotoxic drugs, IVIG should be administered at the minimum dose and rate of infusion practicable.
• Patients with hemolytic anemia or anemia from blood loss (Human parvovirus B19 infection may occur. In case of infection, acute systemic symptoms with fever and severe anemia may occur.)
• Patients with immunological incompetence or immunodeficiency (Human parvovirus B19 infection may occur. In case of infection, continuous anemia may occur.)
• Patients with cerebrovascular and cardiovascular disorders or case history there of for example, (Elderly patients with ischemic disease, cardiovascular disorder, cerebrovascular disorders or case of history thereof: a large bolus administration can cause thrombus or embolism such as cerebral infarction, a myocardial infarction, etc, due to blood viscosity increase.)
• Patients with high risk of thrombus or embolism (Thrombus or embolism may occur due to an increase of blood viscosity due to large bolus administration.)
• Patients with low heart function. (A large bolus administration may cause heart failure or deterioration of heart condition.)
• Aseptic Meningitis Syndrome (AMS) has been reported to occur following high dose (e.g. over 1.0 g per kg body weight) of IVIG treatment or rapid infusion of IVIG. The symptoms of AMS usually begin within several hours to 2 days following IVIG treatment. Discontinuation of IVIG treatment has resulted in remission of AMS within several days without sequelae. AMS is characterized by the following signs and symptoms: severe headache, nuchal rigidity, drowsiness, fever, photophobia, painful eye movements, nausea and vomiting.
• Patients should take caution with IgA deficiency. (IVIG may cause anaphylaxis to patients who have anti-IgA)
• Human normal immunoglobulin may contain blood group antibodies that may act as hemolysins and induce in vivo coating of red blood cells with immunoglobulin, causing a positive direct antiglobulin test result and hemolysis. Delayed hemolytic anemia can develop subsequent to IVIG therapy due to enhanced red blood cell sequestration and acute hemolysis, consistent with intravascular hemolysis, has been reported.
• Non-cardiogenic pulmonary edema has been reported in patients following IVIG treatment.Transfusion-related acute lung injury is characterized by severe respiratory distress, pulmonaryedema, hypoxemia, normal left ventricular function and fever. Symptoms typically appear within 1 to 6 hours after transfusion.
• In case of successive or interval administration, shock or severe abnormal reactions may occur.Accordingly, administration should be done with caution, and catamnesis also should be carefully observed.Especially for children, special caution should be taken for the rate of administration and catamnesis.
• Administration of human normal immunoglobulin for the treatment of Idiopathic Thrombocytopenic Purpura is for symptomatic therapy, not causal treatment.
• In case of Idiopathic Thrombocytopenic Purpura for children, spontaneous remission should be considered.
• In present plasma fractionation process, it is difficult to inactivate or remove human parvovirus B19 etc. completely. Accordingly, possibilities of infection cannot be disregarded, and special caution should be taken for catamnesis.
• Even though a safety plan for the prevention of the spread of infection is prepared, the risk of infection cannot be entirely disregarded since human normal immunoglobulin originates from human blood. This risk should be explained to patients.
• Since human normal immunoglobulin contains anti-A and anti-B, hemolytic anemia may occur when a large bolus is administered to patients with blood type A, B or AB.
• In the case of combined therapy with antibiotics in severe infections, human normal immunoglobulin should be used for patients who show insufficient response to proper antimicrobial chemotherapy.
• There have been published reports that immune globulin intravenous injection is related to disorders of renal function, osmotic renal diseases, including death etc.
• Additional administration to patients with Kawasaki Syndrome should be conducted when the effectiveness of immunoglobulin is insufficient (e.g. symptomatic remission) or additional administration is clearly necessary.(Safety and efficacy for additional administration has not been established)
• Patients should be aware of the risk and discuss with their healthcare professionals and contact them if any signs or symptoms of thrombosis during or after receiving this product develop.
• Healthcare professionals should be aware of the risk for thrombosis with human normal immunoglobulin products and discuss with their patients the risk of thrombosis associated with this product. Monitor patients carefully for signs and symptoms of thrombosis both at the time of infusion and after infusion and encourage patients to report any signs or symptoms.
• Contraindicated in patients who have had a history of anaphylactic or severe systemic hypersensitivity reactions to the administration of human normal immunoglobulin.
• This product is also contraindicated in IgA deficient patients with antibodies to IgA and a history of hypersensitivity.
Interaction with other medicinal products and other forms of interaction
Indications and uses
• There is a possibility that live vaccines (measles, mumps, rubella and varicella vaccine etc.) do not work for the patients who were treated with human normal immunoglobulin. Therefore vaccination should be delayed for 3 months after administration. If human normalimmunoglobulin is administered within 14 days after vaccination, re-vaccination should be taken after more than 3 months of post administration.
• After a large bolus (more than 200 mg/kg) administration for the ITP and Kawasaki disease, use of live vaccines should be delayed more than 6 months. In case of low risk of measles infection, measles vaccination can be delayed for more than 11 months.
Use in Pregnancy and Lactation:
Pregnancy: Safety for a pregnant woman has not been established. The possibility of parvovirus B-19 infection cannot be excluded from the administration of human normal immunoglobulin. In case of parvovirus B-19 infection, fetal disturbances (Abortion, Hydrops fetalis, fetal death) may occur. Human normal immunoglobulin should be given to a pregnant woman only if the expected benefit justifies the possible risk.
Lactation: Use of this product has not been nursing mothers.
Pediatric: Safety for low birth weight infants and neonates has not been established.
Geriatric: Since elderly patients generally have low physiological function, human normal immunoglobulin should be administered with special care.
Overdose may lead to fluid overload and hyperviscosity. Patients at particular risk of complications of fluid overload and hyperviscosity include elderly patients and patients with cardiac or renal impairment.
• Store and transport at +2 OC to +8 OC
• Protect from light
• Do not freeze
• Keep out of the reach and sight of children
NormoglobinTM 2.5: Each box contains 1 vial containing the human normal immunoglobulin BP and an infusion set.